Golden
Jounce Therapeutics

Jounce Therapeutics

Jounce Therapeutics is an immunotherapy company developing therapies to cancer.

All edits

Edits on 1 May 2019
Emerson Spartz
Emerson Spartz approved a suggestion from Golden's AI on 1 May 2019 1:32 am
Edits made to:
Article (+11/-11 characters)

Article

On April 23, 2015 Jounce Therapeutics completed their series B funding round with $56 million in funding from Wellington Management, Redmile Group, Pharmstandard, Omega FundsOmega Funds, Nextech Invest, Inbio Ventures, Foresite Capital, Cormorant Asset Management, and Casdin Capital. 

Edits on 25 Apr 2019
Golden AI
Golden AI edited on 25 Apr 2019 12:52 am
Edits made to:
Infobox (+2 properties)

Infobox

Edits on 29 Mar 2019
Dawson Sewell
Dawson Sewell edited on 29 Mar 2019 10:46 pm
Edits made to:
Infobox (+1 properties)

Infobox

Industry
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 29 Mar 2019 10:33 pm
Edits made to:
Article (+16/-16 characters)

Article

Jounce Therapeutics is a publicly funded, clinical-stage immunotherapy company based in Cambridge, Massachusetts that was founded in 2013 by Drew Pardoll, James P. AllisonJames P. Allison, Louis M. Weiner, Padmanee Sharma, Robert D. Schreiber, and Thomas F. Gajewski. The company is focused on the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits.

Dawson Sewell
Dawson Sewell edited on 29 Mar 2019 10:33 pm
Edits made to:
Infobox (+1 properties)
Documentaries, videos and podcasts (+6 cells) (+179 characters)

Documentaries, videos and podcasts

Title
Date
Link

Java with Jounce Fabien Depis

July 23, 2018

The Promise of Cancer Immunotherapy

October 14, 2016

Infobox

Dawson Sewell
Dawson Sewell edited on 29 Mar 2019 10:29 pm
Edits made to:
Infobox (+1 properties)

Infobox

Industry
Dawson Sewell
Dawson Sewell edited on 29 Mar 2019 10:29 pm
Edits made to:
Infobox (+5/-1 properties)
Timeline (+2 events) (+440 characters)
Article (+649/-15 characters)
Categories (+1/-2 topics)
Related Topics (+1 topics)

Article

Jounce Therapeutics is a publicly funded, clinical-stage immunotherapyimmunotherapy company based in Cambridge, Massachusetts that was founded in 2013 by Drew Pardoll, James P. Allison, Louis M. Weiner, Padmanee Sharma, Robert D. Schreiber, and Thomas F. Gajewski. ItThe company is focused on the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits.



Products

JTX-2011

...



JTX-8064

...



JTX-4014

...



Partnerships

Celgene

...





Funding

Series A

On February 14, 2013 Jounce Therapeutics completed their series A funding round with $47 million in funding from Third Rock Ventures. 

Series B

On April 23, 2015 Jounce Therapeutics completed their series B funding round with $56 million in funding from Wellington Management, Redmile Group, Pharmstandard, Omega Funds, Nextech Invest, Inbio Ventures, Foresite Capital, Cormorant Asset Management, and Casdin Capital. 

Infobox

Categories

Related Topics

Timeline

April 23, 2015

Series B

On April 23, 2015 Jounce Therapeutics completed their series B funding round with $56 million in funding from Wellington Management, Redmile Group, Pharmstandard, Omega Funds, Nextech Invest, Inbio Ventures, Foresite Capital, Cormorant Asset Management, and Casdin Capital. 

March 15, 2013

Series A funding round

On February 14, 2013 Jounce Therapeutics completed their series A funding round with $47 million in funding from Third Rock Ventures. 

Edits on 21 Jan 2019
Golden AI"Changed markets to industries"
Golden AI edited on 21 Jan 2019 10:12 pm
Edits made to:
Infobox (+2/-2 properties)
Edits on 15 Jan 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 15 Jan 2019 2:11 pm
Edits made to:
Article (+24/-24 characters)

Article

Jounce Therapeutics is a publicly funded, clinical-stage immunotherapy company based in Cambridge, MassachusettsCambridge, Massachusetts. It is focused on the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits.

Edits on 13 Jan 2019
Sameeha Sulaiman
Sameeha Sulaiman edited on 13 Jan 2019 12:55 pm
Edits made to:
Article (+1633 characters)
People (+16 cells) (+316 characters)
Further reading (+10 cells) (+486 characters)

Article

Jounce Therapeutics is a publicly funded, clinical-stage immunotherapy company based in Cambridge, Massachusetts. It is focused on the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits.



Jounce's lead product candidate is JTX-2011, a monoclonal antibody that binds to and activates the Inducible T-Cell Co-Stimulator (ICOS), a protein on the surface of certain T-cells that is believed will stimulate an immune response against a patient's cancer. It is intended to treat solid tumors as a single agent and in combination with other therapies. JTX-2011 is being evaluated in Phase 2 clinical trials.



Another product candidate in Jounce's pipeline is JTX-8064. It is the company's lead Beyond T-cell program aimed at disrupting the interaction of targets on tumor-associated macrophages (TAMs) to skew the composition of macrophages within the tumor from immune-suppressing to immune-activating. Jounce is conducting IND enabling studies for this product.



The third product in Jounce's pipeline is JTX-4014, another T-Cell targeting immunotherapy. The company filed its IND application in September 2018 and received approval to move to Phase 1 clinical trials in October 2018.



In July 2016, Jounce entered into a collaboration with Celgene Corporation, which includes options to JTX-2011 and up to four early-stage programs to be selected from a defined pool of B cell, T regulatory cell, and tumor associated macrophage targets emerging from Jounce's Translational Science Platform and an additional option to equally share a checkpoint immuno-oncology program.



People

Name
Role
Related Golden topics

Allison Nance

VP, Regulatory Affairs & Quality Assurance



Anna L. Barry

Senior VP, General Counsel & Secretary



Elizabeth Trehu

Chief Medical Officer



Hugh Cole

Chief Business Officer & Head of Corporate Development



Kim Drapkin

CFO



Richard Murray

President & CEO



Stephen Farrand

Chief Technical Officer



Ted Harding

VP, Human Resources



Further reading

Title
Author
Link
Type

Jounce Therapeutics Announces Major Strategic Collaboration with Celgene Corporation to Develop Next-Generation Immuno-Oncology Therapies for Patients with Cancer

Jounce Therapeutics

Web

Jounce Therapeutics Reports Third Quarter 2018 Financial Results

Jounce Therapeutics, Inc.

Web













Sameeha Sulaiman
Sameeha Sulaiman edited on 12 Jan 2019 8:51 pm
Edits made to:
Infobox (+4/-1 properties)
People (+13 cells) (+134 characters)
Related Topics (+1 topics)

People

Name
Role
Related Golden topics

Drew Pardoll

Founder



James P. Allison

Founder



Louis M. Weiner

Founder



Padmanee Sharma

Founder



Robert Schreiber

Founder



Thomas F. Gajewski

Founder



Infobox

Related Topics

Edits on 10 Jan 2019
Golden AI
Golden AI edited on 10 Jan 2019 10:21 am
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 12 Dec 2018
Golden AI"Import data"
Golden AI edited on 12 Dec 2018 1:10 am
Edits made to:
Infobox (+3 properties)
People (+4 cells) (+44 characters)
Categories (+1 topics)

People

Name
Role
Related Golden topics

Dishant Shah

Employee



Michael Woodbury

Employee



Infobox

Categories

Edits on 19 Jul 2018
Golden AI"Update locations in infobox"
Golden AI edited on 19 Jul 2018 8:53 pm

Infobox

Location
Edits on 16 Jul 2018
Golden AI"Update markets in infobox"
Golden AI edited on 16 Jul 2018 11:38 pm

Infobox

Edits on 29 Jun 2018
Golden AI"Update infobox"
Golden AI edited on 29 Jun 2018 5:50 pm
Edits on 18 Jun 2018
Golden AI"Updating description"
Golden AI edited on 18 Jun 2018 10:52 pm
Edits made to:
Description (+55/-21 characters)
Topic thumbnail

Jounce Therapeutics

Biotechnology company

An immunotherapy company developing therapies to cancer

Edits on 29 May 2018
Golden AI"Initial topic creation"
Golden AI created this topic on 29 May 2018 9:30 pm
Edits made to:
Description (+21 characters)
Categories (+1 topics)
Topic thumbnail

 Jounce Therapeutics

Biotechnology company

Categories

No more activity to show.